69491-59-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyrimidin-5-ylaniline is used as an intermediate in the synthesis of various bioactive compounds, including kinase inhibitors and anticancer agents. It plays a crucial role in the development of new pharmaceuticals with potential therapeutic applications.
Used in Agrochemical Industry:
3-Pyrimidin-5-ylaniline is used in the preparation of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Organic Material Industry:
3-Pyrimidin-5-ylaniline is used in the synthesis of organic materials, enabling the creation of novel compounds with potential applications in various industries, such as electronics, materials science, and more.

InChI:InChI=1/C10H9N3/c11-10-3-1-2-8(4-10)9-5-12-7-13-6-9/h1-7H,11H2

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 591-19-5 m-Bromoaniline 
• 109299-78-7 pyrimidine 5-boronic acid 
• 626-01-7 3-Iodoaniline 
• 69491-54-9 5‐(3‐nitrophenyl)pyrimidine 
• 13331-27-6 m-nitrobenzene boronic acid 

Downstream Products

• 333792-44-2 N-[3-(pyrimidin-5-yl)phenyl]-9H-fluorene-1-carboxamide 
• 333792-99-7 N-[3-(pyrimidin-5-yl)-phenyl]-3-methyl-2-trifluoromethyl-1H-indole-7-carboxamide 
• 374555-37-0 (5-bromoisoquinolin-1-yl)-[3-(pyrimidin-5-yl)phenyl]amine 
• 184173-95-3 N-Acetyl 3-(5-pyrimidyl)aniline 
• 333792-78-2 N-(3-(pyrimidin-5-yl)-phenyl)-9H-carbazole-1-carboxamide 
• 333793-09-2 N-(3-(pyrimidin-5-yl)-phenyl)-2,3-dimethyl-1H-indole-7-carboxamide 
• 1388657-44-0 2-chloro-N-(3-pyrimidin-5-yl-phenyl)acetamide 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS

The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.

Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution

Allosteric modulators of the cannabinoid CB1 receptor have recently been reported as an alternative approach to modulate the CB1 receptor for therapeutic benefits. In this study, we report the design and synthesis of a series of diarylureas derived from PSNCBAM-1 (2). Similar to 2, these diarylureas dose-dependently inhibited CP55,940-induced intracellular calcium mobilization and [35S]GTP-γ-S binding while enhancing [3H]CP55,940 binding to the CB1 receptor. Structure-activity relationship studies revealed that the pyridinyl ring of 2 could be replaced by other aromatic rings and the pyrrolidinyl ring is not required for CB1 allosteric modulation. 34 (RTICBM-74) had similar potencies as 2 in all in vitro assays but showed significantly improved metabolic stability to rat liver microsomes. More importantly, 34 was more effective than 2 in attenuating the reinstatement of extinguished cocaine-seeking behavior in rats, demonstrating the potential of this diarylurea series as promising candidates for the development of relapse treatment of cocaine addiction.

3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) remains an unvalidated antiviral target. A major challenge of specifically targeting HIV RNase H arises from the general lack of selectivity over RT polymerase (pol) and integrase (IN) strand transfer (ST) inhibitions. We report herein the synthesis and biochemical evaluations of three novel 3-hydroxypyrimidine-2,4-dione (HPD) subtypes carefully designed to achieve selective RNase H inhibition. Biochemical studies showed the two subtypes with an N-1 methyl group (9 and 10) inhibited RNase H in low micromolar range without siginificantly inhibiting RT polymerase, whereas the N-1 unsubstituted subtype 11 inhibited RNase H in submicromolar range and RT polymerase in low micromolar range. Subtype 11 also exhibited substantially reduced inhibition in the HIV-1 INST assay and no significant cytotoxicity in the cell viability assay, suggesting that it may be amenable to further structure-activity relationship (SAR) for identifying RNase H inhibitors with antiviral activity.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to amino or pyridylamino cyclobutane derivatives.

Benzimidazole compounds, pharmaceutical compositions containing the compounds and their use

The present patent application discloses compounds having the formula STR1 or a pharmaceutically acceptable salt thereof or an oxide thereof wherein R 3 is STR2 wherein A, B and D each is CH, or one or two of A, B and D is N and the others are CH;R 11 is